Is cabozantinib/cazantinib an anti-angiogenic drug?

Cabozantinib is an anti-angiogenic drug that is a multi-target tyrosine kinase inhibitor and is widely used in tumor treatment.

The uniqueness of Cabozantinib is that it can inhibit multiple targets simultaneously, including MET, VEGFR, RET, etc. This multi-target inhibition capability allows cabozantinib to be effective against a variety of cancer types, especially in inhibiting tumor angiogenesis. By inhibiting the activity of vascular endothelial factor receptors (such as VEGFR2), cabozantinib can effectively block the formation of new blood vessels in tumors, thereby cutting off the nutrient supply to tumors and causing tumor cells to undergo apoptosis due to hypoxia. This mechanism is one of the key roles of cabozantinib as an anti-angiogenic drug.

Cabozantinib has shown significant efficacy in a variety of tumors, including kidney cancer, thyroid cancer, liver cancer, non-small cell lung cancer, etc. Especially after being verified in multiple clinical trials, the drug has been approved by the US FDA for the treatment of advanced thyroid cancer and has prolonged the survival of many patients.

Research in recent years has also found that cabozantinib shows strong potential in combination immunotherapy. For example, when used in combination with immune checkpoint inhibitors (such asanti-PD1), cabozantinib can enhance anti-tumor immunity by regulating the tumor microenvironment, thereby further improving the therapeutic effect.

The pharmacokinetic properties of cabozantinib also support its use as an effective anti-angiogenic agent. The drug's peak time, half-life, steady-state time and other parameters in the body all indicate that it has good drug stability and sustained therapeutic effect.